<DOC>
	<DOCNO>NCT00044564</DOCNO>
	<brief_summary>In patient renal cell cancer , frequent method treatment include surgery , chemotherapy , hormonal therapy , immunotherapy . Renal cell carcinoma usually consider radioresistant chemoresistant . In patient metastatic disease , option limit . The taxanes among commonly use class chemotherapy agent clinical oncology today effective renal cancer ; development Bay 59-8862 target taxane-resistant tumor current protocol design test safety efficacy Bay 59-8862 patient advance renal cell carcinoma .</brief_summary>
	<brief_title>Evaluation Bay 59-8862 Patients With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>measurable disease define presence least one measurable lesion prior immunotherapy ( 2 regimen ) prior radiotherapy permit least 4 week must elapse prior enter study life expectancy least 12 week adequate bone marrow , liver kidney function exclude medical condition like : preexisting neuropathy , active heart diseases ischemia , serious infection , HIV infection , chronic hepatitis B C , brain metastasis , seizure , hypersensitivity taxanes , organ transplant , previous cancer exclude therapy medication , previous concomitant : anticancer chemotherapy immunotherapy study within 4 week prior study entry ; two prior anticancer chemotherapy regimens ; radiotherapy study within 4 week prior study entry ; bone marrow transplant others : pregnant breastfeeding patient ; men woman enrol trial must use adequate barrier birth control measure course trial ; substance abuse , medical , psychological social condition may interfere patient 's participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Taxane</keyword>
	<keyword>Renal Cell Carcinoma</keyword>
	<keyword>Advanced Renal Cell Carcinoma</keyword>
</DOC>